• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Aerie Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

Aerie Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 25 pages
  • GlobalData

Aerie Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Aerie Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aerie Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aerie Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Aerie Pharmaceuticals, Inc. Snapshot
Aerie Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Aerie Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Aerie Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Aerie Pharmaceuticals, Inc. – Pipeline Products Glance
Aerie Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Aerie Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Aerie Pharmaceuticals, Inc. – Drug Profiles
AR-102
Product Description
Mechanism of Action
R&D Progress
AR-12286
Product Description
Mechanism of Action
R&D Progress
AR-12286 + Latanoprost
Product Description
Mechanism of Action
R&D Progress
Aerie Pharmaceuticals, Inc. – Pipeline Analysis
Aerie Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Aerie Pharmaceuticals, Inc. Pipeline Products By Target
Aerie Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Aerie Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 22, 2009: Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results In Glaucoma Patients In A Phase IIa Study
Financial Deals Landscape
Aerie Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Aerie Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Aerie Pharmaceuticals Secures $21 Million In Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS